Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases

Overview

Journal Front Pharmacol

Date 2022 Jan 31

PMID 35095513

Authors

Fangling Zhang

Xiaolin Xiao

Yong Li

Hefei Wu

Xinyu Deng

Yinxiao Jiang

Wenwen Zhang

Jian Wang

Xiao Ma

Yanling Zhao

Affiliations

Soon will be listed here.

Abstract

GPBAR1, a transmembrane G protein-coupled receptor for bile acids, is widely expressed in multiple tissues in humans and rodents. In recent years, GPBAR1 has been thought to play an important role in bile homeostasis, metabolism and inflammation. This review specifically focuses on the function of GPBAR1 in cholestatic liver disease and summarizes the various pathways through which GPBAR1 acts in cholestatic models. GPBAR1 mainly regulates cholestasis in a holistic system of liver-gallbladder-gut formation. In the state of cholestasis, the activation of GPBAR1 could regulate liver inflammation, induce cholangiocyte regeneration to maintain the integrity of the biliary tree, control the hydrophobicity of the bile acid pool and promote the secretion of bile HCO . All these functions of GPBAR1 might be clear ways to protect against cholestatic diseases and liver injury. However, the characteristic of GPBAR1-mediated proliferation increases the risk of proliferation of cholangiocarcinoma in malignant transformed cholangiocytes. This dichotomous function of GPBAR1 limits its use in cholestasis. During disease treatment, simultaneous activation of GPBAR1 and FXR receptors often results in improved outcomes, and this strategy may become a crucial direction in the development of bile acid-activated receptors in the future.

Citing Articles

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.

Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E Cells. 2024; 13(18.

PMID: 39329760 PMC: 11429758. DOI: 10.3390/cells13181580.

Increase in bile acids after sleeve gastrectomy improves metabolism by activating GPBAR1 to increase cAMP in mice with nonalcoholic fatty liver disease.

Li G, Xu X, Chai L, Guo Q, Wu W Immun Inflamm Dis. 2024; 12(7):e1149.

PMID: 39031498 PMC: 11259005. DOI: 10.1002/iid3.1149.

Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease.

Masse K, Lu V Front Endocrinol (Lausanne). 2023; 14:1169624.

PMID: 37560311 PMC: 10407565. DOI: 10.3389/fendo.2023.1169624.

Bile acid-mediated signaling in cholestatic liver diseases.

Zeng J, Fan J, Zhou H Cell Biosci. 2023; 13(1):77.

PMID: 37120573 PMC: 10149012. DOI: 10.1186/s13578-023-01035-1.

References

Li A, Xie X, Qi W, Wang W, Ma J, Zhao D . TGR5 promotes cholangiocarcinoma by interacting with mortalin. Exp Cell Res. 2020; 389(2):111855. DOI: 10.1016/j.yexcr.2020.111855. View

Gong Z, Zhou J, Zhao S, Tian C, Wang P, Xu C . Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis. Oncotarget. 2016; 7(51):83951-83963. PMC: 5356637. DOI: 10.18632/oncotarget.13796. View

Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A . Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun. 2007; 362(4):793-8. DOI: 10.1016/j.bbrc.2007.06.130. View

Huang S, Ma S, Ning M, Yang W, Ye Y, Zhang L . TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice. Metabolism. 2019; 99:45-56. DOI: 10.1016/j.metabol.2019.07.003. View

Razumilava N, Gores G . Cholangiocarcinoma. Lancet. 2014; 383(9935):2168-79. PMC: 4069226. DOI: 10.1016/S0140-6736(13)61903-0. View

Jones H, Alpini G, Francis H . Bile acid signaling and biliary functions. Acta Pharm Sin B. 2015; 5(2):123-8. PMC: 4629225. DOI: 10.1016/j.apsb.2015.01.009. View

Grasset E, Puel A, Charpentier J, Collet X, Christensen J, Terce F . A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metab. 2017; 25(5):1075-1090.e5. DOI: 10.1016/j.cmet.2017.04.013. View

Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann A . Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008; 51(6):1831-41. DOI: 10.1021/jm7015864. View

Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M . A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278(11):9435-40. DOI: 10.1074/jbc.M209706200. View

10.

Zambad S, Tuli D, Mathur A, Ghalsasi S, Chaudhary A, Deshpande S . TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity. Diabetes Metab Syndr Obes. 2014; 7:1-14. PMC: 3873233. DOI: 10.2147/DMSO.S50209. View

11.

Ono E, Inoue J, Hashidume T, Shimizu M, Sato R . Anti-obesity and anti-hyperglycemic effects of the dietary citrus limonoid nomilin in mice fed a high-fat diet. Biochem Biophys Res Commun. 2011; 410(3):677-81. DOI: 10.1016/j.bbrc.2011.06.055. View

12.

Ladurner A, Zehl M, Grienke U, Hofstadler C, Faur N, Pereira F . Allspice and Clove As Source of Triterpene Acids Activating the G Protein-Coupled Bile Acid Receptor TGR5. Front Pharmacol. 2017; 8:468. PMC: 5511840. DOI: 10.3389/fphar.2017.00468. View

13.

Keitel V, Haussinger D . TGR5 in the biliary tree. Dig Dis. 2011; 29(1):45-7. DOI: 10.1159/000324127. View

14.

Zhong M . TGR5 as a therapeutic target for treating obesity. Curr Top Med Chem. 2010; 10(4):386-96. DOI: 10.2174/156802610790980576. View

15.

Li M, Cai S, Boyer J . Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects Med. 2017; 56:45-53. PMC: 5662014. DOI: 10.1016/j.mam.2017.06.001. View

16.

Rossen N, Fuentes S, Boonstra K, DHaens G, Heilig H, Zoetendal E . The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis. 2014; 9(4):342-8. DOI: 10.1093/ecco-jcc/jju023. View

17.

Erice O, Labiano I, Arbelaiz A, Santos-Laso A, Munoz-Garrido P, Jimenez-Aguero R . Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(4 Pt B):1335-1344. DOI: 10.1016/j.bbadis.2017.08.016. View

18.

Baghdasaryan A, Fuchs C, Osterreicher C, Lemberger U, Halilbasic E, Pahlman I . Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol. 2015; 64(3):674-81. DOI: 10.1016/j.jhep.2015.10.024. View

19.

Lo S, Li Y, Cheng K, Niu C, Cheng J, Niu H . Ursolic acid activates the TGR5 receptor to enhance GLP-1 secretion in type 1-like diabetic rats. Naunyn Schmiedebergs Arch Pharmacol. 2017; 390(11):1097-1104. DOI: 10.1007/s00210-017-1409-9. View

20.

Ichikawa R, Takayama T, Yoneno K, Kamada N, Kitazume M, Higuchi H . Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology. 2012; 136(2):153-62. PMC: 3403261. DOI: 10.1111/j.1365-2567.2012.03554.x. View